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OBJECTIVE — Type 2 diabetes is the leading cause of end-stage renal disease worldwide.
Aside from hyperglycemia and hypertension, other metabolic factors may determine renal out-
come. We examined risk associations of metabolic syndrome with new onset of chronic kidney
disease (CKD) in 5,829 Chinese patients with type 2 diabetes enrolled between 1995 and 2005.
RESEARCH DESIGN AND METHODS — Metabolic syndrome was deﬁned by Na-
tionalCholesterolEducationProgramAdultTreatmentPanelIIIcriteriawiththeAsiandeﬁnition
of obesity. Estimated glomerular ﬁltration rate (eGFR) was calculated using the abbreviated
Modiﬁcation of Diet in Renal Disease formula modiﬁed for the Chinese population. New onset
of CKD was deﬁned as eGFR 60 ml/min per 1.73 m
2 at the time of censor. Subjects with CKD
at baseline were excluded from the analysis.
RESULTS — After a median follow-up duration of 4.6 years (interquartile range: 1.9–7.3
years), 741 patients developed CKD. The multivariable-adjusted hazard ratio (HR) of CKD was
1.31(95%CI1.12–1.54,P0.001)forsubjectswithmetabolicsyndromecomparedwiththose
without metabolic syndrome. Relative to subjects with no other components of metabolic syn-
dromeexceptfordiabetes,thosewithtwo,three,four,andﬁvemetabolicsyndromecomponents
had HRs of an increased risk of CKD of 1.15 (0.83–1.60, P  0.407) 1.32 (0.94–1.86, P 
0.112), 1.64 (1.17–2.32, P  0.004), and 2.34 (1.54–3.54, P  0.001), respectively. The
metabolic syndrome traits of central obesity, hypertriglyceridemia, hypertension, and low BMI
were independent predictors for CKD.
CONCLUSIONS — The presence of metabolic syndrome independently predicts the devel-
opment of CKD in subjects with type 2 diabetes.
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T
here is now a pandemic of diabetes
and obesity in both developing and
developed countries (1,2). Apart
from predicting type 2 diabetes and car-
diovascular and all-cause mortality (3),
metabolic syndrome has also been linked
to chronic kidney disease (CKD) (4,5).
However,mostoftheselatterstudieswere
either cross-sectional in nature or con-
ducted in general populations. Diabetes
and hypertension are the main driving
forces for the rising epidemic of CKD and
end-stage renal disease (ESRD) (6). Given
that components of metabolic syndrome
such as hypertension, hyperlipidemia,
and obesity are common among subjects
with type 2 diabetes, the impacts of clus-
tering of these risk factors in the form of
metabolic syndrome on CKD in individ-
uals with type 2 diabetes remain to be
established.
Furthermore, there is now consistent
data showing that Asian diabetic popula-
tions, including Chinese, have a higher
risk of renal complications than their
Caucasian counterparts (7). In a large-
scale multinational survey, up to 60% of
Asian patients with type 2 diabetes had
albuminuria,comparedwith30–40%re-
ported in the Western population (8).
Against this background, we exam-
ined the independent risk associations of
metabolic syndrome and its components
with CKD in Chinese patients with type 2
diabetes, using the Hong Kong Diabetes
Registry.
RESEARCH DESIGN AND
METHODS— The Hong Kong Diabe-
tes Registry was established in 1995 as
part of a continuous quality-improve-
mentprogramatthePrinceofWalesHos-
pital, Hong Kong. Between 1995 and
2005, a total of 7,838 patients from com-
munity and hospital clinics, as well as pa-
tientsnewlydischargedfromthehospital,
was enrolled in this Registry. Patients
with type 1 diabetes (n  334) deﬁned as
acute presentation with diabetic ketoaci-
dosis, heavy ketonuria (3), or a con-
tinuous requirement of insulin within 1
year of diagnosis were excluded from this
analysis. Patients with estimated glomer-
ular ﬁltration rate (eGFR) 60 ml/min
per 1.73 m
2 (n  540) and a preexisting
macrovascular complication (n  1,135)
at enrollment were not included. A mac-
rovascular complication was deﬁned as
ischemic heart disease, cerebrovascular
disease, or peripheral vascular disease.
A total of 5,829 Chinese patients with
type 2 diabetes were included in the ﬁnal
analysis. All subjects had a compre-
hensive assessment of risk factors and
complications based on the European
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wasobtainedfromtheChineseUniversity
of Hong Kong Clinical Research Ethics
Committee, and written consent was ob-
tained from all patients for data analysis
and research purposes.
Detailsoftheclinicalassessmentsand
laboratory assays were described previ-
ously (10). In brief, sitting blood pressure
was measured in both arms using a Di-
namapmachineafteratleast5minofrest-
ing, and the mean value was used for
analysis. Waist circumference (to the
nearest centimeter) was measured by a
plastictapeatthenarrowestlevelbetween
the xiphisternum and umbilicus. Fun-
duscopy was performed by physicians
with training in diabetes or ophthalmolo-
gists through dilated pupils. Retinopathy
was deﬁned by the presence of dot and
blot hemorrhages, hard exudates, cotton
wool spots, neovascularization, laser
scars, or a history of vitrectomy. Sensory
neuropathy was diagnosed by two of
these three features: reduced sensation to
monoﬁlament examination in any part of
thesolewithnormalskin,ascoreof6of
8 (aged 65 years) or 4 of 8 (aged 65
years old) using a graduated tuning fork,
or abnormal sensation in lower limbs.
Fasting blood samples were taken for
measurement of plasma glucose, A1C,
lipid proﬁle (total cholesterol, HDL cho-
lesterol, triglycerides, and calculated LDL
cholesterol), and renal function. A sterile
random spot urine sample was used to
measure the albumin-to-creatinine ratio
(ACR). Microalbuminuria was deﬁned as
either ACR of 2.5–30 mg/mmol in
women or 3.5–30 mg/mmol in men.
Macroalbuminuria was deﬁned as ACR
30 mg/mmol. All laboratory assays
were performed at the Department of
Chemical Pathology, the Prince of Wales
Hospital,whichisaccreditedbytheRoyal
College of Pathologists of Australasia.
Glomerular ﬁltration rate was calculated
usingtheabbreviatedequationdeveloped
by the Modiﬁcation of Diet in Renal Dis-
ease (MDRD) study with modiﬁcation for
the Chinese population: eGFR  186 
[SCR  0.011]
1.154  [age]
0.203 
[0.742 if female]  1.233, where SCR is
serum creatinine expressed as micro-
moles per liter (original milligrams per
deciliter converted to micromoles per li-
ter) and 1.233 is the adjusting coefﬁcient
for Chinese (11).
Metabolic syndrome was diagnosed
accordingtotheNationalCholesterolEd-
ucation Program Adult Treatment Panel
III criteria with Asian modiﬁcations for
waist circumferences (12). Because pa-
tients already had diabetes, metabolic
syndrome was considered to be present
if two or more of the following four cri-
teria were met: waist circumference
80 cm in women and 90 cm in men,
fasting plasma triglyceride 1.7
mmol/l, fasting HDL cholesterol 1.0
mmol/l in men and 1.3 mmol/l in
women, and blood pressure 130/85
mmHg. Patients who were taking anti-
hypertensive drugs including ACE in-
hibitors and angiotensin receptor
blockers were recorded as having ele-
vated blood pressure. Patients who
were using ﬁbrates and/or statins were
recordedasfulﬁllingonelipidcriterion.
Clinical outcomes
All clinical end points including hospital
admissions and mortality were censored
on 30 July 2005 using databases from the
HA Central Computer System, which
recordsadmissionstoallpublichospitals.
These databases, including the Hong
Kong Death Registry, were matched by a
unique identiﬁcation number, the Hong
Kong Identity Card number, which is
compulsory for all residents in Hong
Kong and used by all government depart-
ments and major organizations. Serum
creatininemeasurementscollectedwithin
6 months of the censored date and hospi-
talization discharge diagnoses were used
to derive eGFR for end point deﬁnition.
Hospital discharge diagnoses were coded
by the ICD-9. Hospitalization with CKD
eventwasdeﬁnedas1)hospitalizationwith
a diagnosis of diabetes with renal manifes-
tations (code 250.4), CKD (code 585), or
unspeciﬁed renal failure (code 586) or 2)
dialysis (ICD-9 procedure code 39.95) or
peritoneal dialysis (ICD-9 procedure
code 54.98). In this study, the end point
Table1—Baselineclinicalandbiochemicalcharacteristicsof5,829Chinesepatientswithtype
2diabeteswithandwithoutmetabolicsyndromeasdeﬁnedbyNationalCholesterolEducation
Program Adult Treatment Panel III criteria
Metabolic syndrome
P value No Yes
n 2,844 2,985
Age (years) 52.6  13.1 55.6  12.8 0.001
Men (%) 56.3 43.7 0.001
Smoking status (%)
Nonsmoker 70.2 73.9
Ex-smoker 15.6 13.0
Current smoker 14.2 13.1 0.003*
Duration of diabetes (years) 6.0  6.0 6.5  6.3 0.003
BMI (kg/m
2 ) 23.71  3.3 26.5  4.2 0.001
Waist circumference (cm)
Men 84.8  8.3 92.4  10.0 0.001
Women 77.8  7.6 87.6  9.7 0.001
Systolic blood pressure (mmHg) 127  19 139  18 0.001
Diastolic blood pressure (mmHg) 74  10 78  11 0.001
A1C (%) 7.58  1.93 7.78  1.70 0.001
Fasting plasma glucose (mmol/l) 8.50  3.27 8.91  3.20 0.001
Triglycerides (mmol/l) 1.02 (0.77–1.32) 1.90 (1.32–2.62) 0.001
HDL cholesterol (mmol/l)
Men 1.36  0.33 1.06  0.28 0.001
Women 1.56  0.37 1.25  0.31 0.001
LDL cholesterol (mmol/l) 3.18  0.91 3.25  0.99 0.001
Plasma creatinine (mol/l) 74.0 (62.0–88.0) 76.0 (63.0–90.0) 0.001
eGFR (ml/min per 1.73m
2) 117.8  29.4 109.0  29.2 0.001
Urinary ACR 1.15 (0.61–3.17) 2.42 (085–11.52) 0.001
Albuminuria status
Normal (%) 73.3 52.7
Microalbuminuria (%) 21.0 32.4
Macroalbuminuria (%) 5.7 14.9 0.001*
Neuropathy (%) 21.0 23.1 0.047*
Retinopathy (%) 19.7 23.8 0.001*
Data are means  SD or median (interquartile range) unless otherwise indicated. *Pearson 	
2 test.
Metabolic syndrome and new-onset CKD
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per 1.73 m
2 or the ﬁrst hospitalization
with CKD event.
Statistical analysis
All data are means  SD or median (in-
terquartile range). For between-group
comparisons, the 	
2 test was used for cat-
egorical variables, and the Student’s t test
or ANOVA was used for continuous vari-
ables.Coxregressionanalysiswasapplied
by the backward stepwise method with
CKD as the dependent variable. The met-
abolic syndrome (or its components) and
other known risk factors for CKD were
included in the model. Hazard ratios
(HRs) with 95% CIs were calculated. Be-
fore analysis, the skewed distribution of
ACR and triglyceride was normalized by
logarithmic transformation. A Kaplan-
Meier curve was used to show the risk
relationship between patients with and
without the metabolic syndrome and pa-
tients with different components of the
metabolic syndrome. P (two sided)
0.05 was considered to be signiﬁcant.
Statistical analysis was performed using
the Statistical Package for Social Science
(version 13.0 for Windows; SPSS, Chi-
cago, IL).
RESULTS— The mean  SD age of
the cohort was 54.1  13.0 years, and
45.5% were men. The mean duration of
diabetes was 6.23  6.17 years. The fre-
quency of metabolic syndrome was 51.2%
(n2,985).Afteramedianobservationpe-
riod of 4.6 years (interquartile range 1.9–
7.3),741patients(12.7%)developedCKD.
Table 1 compares the baseline demo-
graphic, clinical, and biochemical charac-
teristics of patients with and without
metabolic syndrome. Patients in the former
group were older and had a longer dura-
tion of diabetes and worse glycemic con-
trol. In addition, compared with the
group without metabolic syndrome,
thosewithmetabolicsyndromehadtwice
the frequency of albuminuria and had a
lower eGFR at baseline.
The relationship between CKD and
metabolic syndrome was analyzed using
Cox regression analysis, with adjustment
for confounding variables including age,
sex, smoking status, duration of diabetes,
A1C,BMI,andalbuminuria.Patientswith
two, three, four, and ﬁve metabolic syn-
drome components had sequential in-
creases in multivariable-adjusted HRs of
CKD of 1.15 (95% CI 0.83–1.60, P 
0.407), 1.32 (0.94–1.86, P  0.112),
1.64 (1.17–2.32, P  0.004), and 2.34
(1.54–3.54, P  0.001), respectively
(Fig. 1). The multivariable-adjusted HR
of CKD for subjects with metabolic syn-
drome compared with that without met-
abolic syndrome was 1.31 (1.12–1.54,
P  0.001).
Among the components of metabolic
syndrome, central obesity, hypertension,
and hypertriglyceridemia, but not HDL
cholesterol (HR 1.12 [95% CI 0.95–
1.32]), were associated with increased risk
of CKD. Other risk factors included age,
male sex, disease duration, A1C, retinopa-
thy, microalbuminuria, and macroalbu-
minuria, with the latter two conferring
two- and ﬁvefold increased risk of CKD,
respectively (Table 2). Paradoxically, low
BMI was also associated with increased
risk of CKD. Figure 2 shows the risk as-
Figure 1—Cumulative probability of new-onset CKD according to number of metabolic syndrome components.
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ﬁed by median values of waist and BMI.
Compared with patients with the highest
BMI and lowest waist circumference,
those with the highest waist circumfer-
ence and lowest BMI had the highest HR
of CKD.
CONCLUSIONS — In this prospec-
tive analysis of a relatively large cohort of
patients with type 2 diabetes, we con-
ﬁrmed the risk association between met-
abolic syndrome and CKD independent
ofconventionalriskfactorsincludingage,
male sex, glycemic control, disease dura-
tion, and albuminuria. This ﬁnding is
strengthened by the stepwise increase in
HRforCKDwithanincreasingnumberof
metabolic syndrome components.
Among the latter, central obesity, hyper-
triglyceridemia, and hypertension were
the three main metabolic syndrome traits
related to CKD in this cohort. These three
factors were also found to predict all-
cause and cardiovascular mortality in a
community-based Hong Kong Chinese
cohort (13).
Of note, we observed the additive ef-
fects of high waist circumference and low
BMI on risk of CKD independent of met-
abolic control. There is now general con-
sensus that waist circumference as a
surrogate of visceral adiposity (14) is
more strongly correlated with adverse
metabolic risks including high blood
pressure, dyslipidemia, and increased in-
sulinresistance(15).Lamacchiaetal.(16)
observed recently in subjects with type 2
diabetes that waist circumference but not
BMI was associated with an increased re-
nal resistive index, a parameter that re-
ﬂects intrarenal arteriosclerosis and
glomerulosclerosis.Increasedadiposetis-
sue, especially that of visceral origin, is a
rich source of inﬂammatory cytokines
and growth factors including leptin, tu-
mor necrosis factor-
, and interleukin-6
(17). In a separate cohort of Chinese pa-
tients with type 2 diabetes with nephrop-
athy, we reported aberrant activation and
expression of inﬂammatory cytokines or
adhesion molecules, which can have di-
rect effects on renal hemodynamics and
glomerular cellularity (18). Although low
BMI may reﬂect lipolysis and muscle
wasting due to hyperglycemia and insuf-
ﬁcient insulin action, the risk conferred
by low BMI on CKD in our cohort was
independentofA1C.IntheJapanesepop-
ulation,obesityisanindependentpredic-
tor for end-stage renal disease in the
general population (19), although low
BMI and increased waist circumference
are independent predictors for diabetes
(20). Thus, with the onset of diabetes, the
effect of body composition and/or distri-
bution may take on different prognostic
signiﬁcance.
In this cohort, hypertriglyceridemia
but not a low HDL cholesterol level was
predictive of CKD development. In keep-
ing with the clinical observations on lipo-
toxicity and renal damage, there are
experimental studies showing the stimu-
latory effects of lipids on mesangial cell
proliferation and matrix deposition, in
addition to recruitment of inﬂammatory
cells and synthesis of inﬂammatory cyto-
kines (21). In a recent meta-analysis of
40,000 individuals, the use of hydroxym-
ethylglutaryl-CoA inhibitors attenuated
the rate of progression of renal impair-
ment and reduced proteinuria (22). In a
post hoc analysis of a clinical study
comparing the effects of fenoﬁbrate and
placebo treatment on progression of
coronary atherosclerosis, fenoﬁbrate
was associated with a greater reduction
in albuminuria in patients with type 2
diabetes (23).
Figure 2—Percentage of patients with new-onset CKD stratiﬁed by medians of waist circumfer-
ence and BMI.
Table 2—Cox regression analysis showing the association of CKD with individual metabolic
syndrome traits and covariables in Chinese patients with type 2 diabetes
Independent variables HR (95% CI) P value
Male sex 1.30 (1.10–1.53) 0.002
Age per year 1.04 (1.04–1.05) 0.001
Duration of diabetes (year) 1.02 (1.01–1.03) 0.001
A1C 1.11 (1.07–1.16) 0.001
Microalbuminuria 2.16 (1.77–2.63) 0.001
Macroalbuminuria 5.82 (4.75–7.14) 0.001
BMI 0.97 (0.94–0.99) 0.008
Retinopathy 1.79 (1.52–2.10) 0.001
Metabolic syndrome traits
Hypertension 1.37 (1.09–1.72) 0.007
Central obesity 1.58 (1.26–1.98) 0.001
Hypertriglyceridemia 1.24 (1.06–1.44) 0.006
Metabolic syndrome and new-onset CKD
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be associated with development of car-
diovascular diseases (3). In our current
study of the Chinese diabetic population,
we observed that metabolic syndrome in-
creased the risk of CKD. Moreover, CKD
per se is an independent determinant of
atherosclerotic diseases and the two con-
ditions often coexist. In a separate analy-
ses of this cohort, we have demonstrated
that albuminuria (24) and estimated GFR
(25) were strongly predictive of cardio-
vascular outcome. We proposed that
the same metabolic risk factors are op-
erative in the progression of both con-
ditions. In this connection, increased
oxidative stress, chronic inﬂammation,
increased ﬁbrogenic activity, and endo-
thelial dysfunction are common under-
lying pathological events.
Our study has several limitations.
First, baseline measurements of serum
creatininewerebasedonasinglecollec-
tion and may not fully reﬂect the back-
ground renal function, especially in the
presence of intercurrent illness. At
baseline,allclinicalandbiochemicalas-
sessments were performed in an outpa-
tient setting when the patient was
clinically stable. Second, although diabe-
tes may be the main culprit for the new on-
set of CKD in this prospective cohort, other
causes such as ischemic nephrosclerosis,
obstructive uropathy, and glomerulone-
phritis may also contribute to deterioration
of renal function. Third, some investigators
have suggested overestimation of the prev-
alenceofstage4to5CKDusingtheoriginal
MDRD equations. However, the current
modiﬁed MDRD formula has been vali-
dated in Chinese populations (11).
Despite these limitations, the rela-
tively large sample size of the present co-
hort with detailed phenotyping and a
relatively long observational period, aver-
aging 5 years, is an important strength of
our study to support the causal relation-
ship between metabolic factors and renal
dysfunction. In summary, the presence of
metabolic syndrome is associated with an
increased risk of development of CKD.
Ourstudyhasexpandedthecurrentbody
of knowledge on the possible causes of
diabeticnephropathyandhighlightsmet-
abolic syndrome as a major problem for
which individuals with diabetes who are
at high risk of cardiorenal complications
need treatment.
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